1. Incidence and prognostic implications of acute kidney injury on admission in patients with community-acquired pneumonia
- Author
-
Ahsan R. Akram, James D. Chalmers, Adam T. Hill, Gourab Choudhury, Pallavi Mandal, and Aran Singanayagam
- Subjects
Pulmonary and Respiratory Medicine ,Male ,medicine.medical_specialty ,medicine.medical_treatment ,Renal function ,Angiotensin-Converting Enzyme Inhibitors ,Critical Care and Intensive Care Medicine ,Severity of Illness Index ,Statistics, Nonparametric ,Community-acquired pneumonia ,Risk Factors ,Internal medicine ,medicine ,Humans ,Rifle ,Renal replacement therapy ,Prospective Studies ,Aged ,Chi-Square Distribution ,business.industry ,Incidence ,Acute kidney injury ,Odds ratio ,Pneumonia ,Acute Kidney Injury ,Middle Aged ,medicine.disease ,Prognosis ,Respiration, Artificial ,Surgery ,Community-Acquired Infections ,Renal Replacement Therapy ,C-Reactive Protein ,Creatinine ,Female ,Cardiology and Cardiovascular Medicine ,business ,Angiotensin II Type 1 Receptor Blockers ,Biomarkers ,Kidney disease - Abstract
A consensus definition of acute kidney injury (AKI)-the risk, injury, failure, loss, and end-stage kidney disease (RIFLE) classification-predicts mortality in general hospital and ICU populations. We aimed to assess its value on admission in patients with community-acquired pneumonia (CAP).A prospective observational study with CAP was carried out. We classified each patient according to his or her maximum RIFLE class using admission creatinine (risk, ≥ 1.5 × baseline creatinine; injury, ≥ 2 × baseline; failure, ≥ 3 × baseline; no-AKI,1.5 × baseline). Outcomes were 30-day mortality, requirement for mechanical ventilation and inotropic support (MV/IS), and requirement for renal replacement therapy (RRT).A total of 1,241 patients were included (no-AKI, 1,018; risk, 130; injury, 63; failure, 30). On multivariate analysis, factors predicting development of AKI include severity of pneumonia (adjusted odds ratio [AOR], 1.74; 95% CI, 1.46-2.08; P.0001), elevated C-reactive protein (AOR, 1.04; 95% CI, 1.03-1.06; P.0001), and prior use of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin-II-receptor blockers (AIIBs) (AOR, 1.77; 95% CI, 1.19-2.58; P = .005). Adjusting for severity of pneumonia, RIFLE criteria independently predicted 30-day mortality (AOR, 1.48; 95% CI, 1.15-1.91; P = .002), requirement for MV/IS (AOR, 2.22; 95% CI, 1.74-2.83; P.0001), and RRT (AOR, 3.20; 95% CI, 2.01-5.11; P.0001). Prior use of ACEIs or AIIBs was not associated with adverse outcome in either the entire cohort or patients without AKI.The RIFLE classification is a simple tool to assess and classify AKI on admission and independently predicts 30-day mortality and the need for MV/IS and RRT in patients with CAP.
- Published
- 2010